Family · Pharmaceutical analytical standards
Finerenone
A non-steroidal mineralocorticoid receptor antagonist, blocking the receptor for aldosterone. It was approved in the United States in 2021 for chronic kidney disease associated with type 2 diabetes, and later also for heart failure. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?Its discovery started from some 1,4-dihydropyridines, the same chemical family as nifedipine, found by high-throughput screening: by optimising them, chemists arrived at a dihydronaphthyridine.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
